Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 26, Issue 3, Pages 111-113Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2015.01.004
Keywords
anabolic window; PTH; bisphosphonates; denosumab; sclerostin; bone remodeling
Categories
Ask authors/readers for more resources
Maximization of the anabolic effects of intermittent administration of parathyroid hormone (PTH) has recently been at the forefront of clinical research in the area of osteoporosis, with the 'anabolic window' concept as its main driving force. The outcome of these attempts, however, has not been encouraging. This article examines whether the concept itself is based on sound evidence, related pathophysiological aspects, and whether the new anti-sclerostin antibodies could have extended anabolic action.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available